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There is no question that accurate staging, particularly of the mediastinum, plays acentral role in our current approach to lung cancer. The status of nodal involvement
has a profound impact on prognosis, and it is a critical decision point in our treatment
algorithms. One could equate initiating a treatment plan without clearly defining the
mediastinal node status with setting out on a journey without knowing exactly where one
is trying to go, as opposed to programming a global positioning system for the shortest,
fastest (or perhaps most cost-effective?) route.
There is also no question that, at least in North America, we have not done a good
job of assessing nodes in lung cancer. An assessment of surgical lung cancer cases in 2001
found that only 27% of patients underwent preoperative invasive mediastinal staging, and
in half of the mediastinoscopies not even a single node was sampled.1 A more recent study
associated better long-term outcomes with a greater extent of preoperative staging.2 There
are data that addressing variations in care would save many times more lives than what we
hail as “breakthrough advances” in new drugs.2–4
Furthermore, there is a focus on quality of care in medicine. There is a push to
develop process measures (quality metrics) as a tool to assess in real-time when we are
doing well and when we are not, much like the interest in biomarkers as prognostic or
predictive indicators. Very few validated quality metrics exist in lung cancer; at this point
we have more speculative measures than validated ones. Many groups are actively trying
to develop such metrics. An obvious candidate, for the reasons noted above, is a measure
of the quality of mediastinal staging.
Osarogiagbon et al5 deserve praise for an ongoing effort to develop data to help
define quality indicators, as is addressed in an article in this issue of the Journal of
Thoracic Oncology. They have assessed the extent of mediastinal staging at the time of
resection (i.e., mediastinal node dissection [MLND], systematic sampling [SS], random
sampling [RS], and no sampling [NS]) in a regional quality improvement project
involving all lung cancer resections in the Memphis area from 2004 to 2007. They
compared the extent of mediastinal staging as determined by the surgeon (the procedure
name in the title of the operative report), by an independent review of the operative
procedure, and by the pathology report.
Osarogiagbon and coworkers1,2,5 found that the extent of nodal staging at the time
of resection was poor, consistent with other reports. By the surgeons assessment, 48% had
NS, 8% RS, and 45% MLND. However, by the pathology report, 42% had NS, 50% RS,
9% SS, and none were a MLND. What is striking is the extremely low concordance
between how the mediastinal assessment was classified by the surgeon, by an independent
audit of the procedure, and by the pathology report. In fact, most of the concordant cases
were those with no nodes assessed; with exclusion of these the concordance was only
11%. This essentially eliminates, at least at this time, using the extent of intraoperative
node assessment as a quality indicator.
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Is it a matter of documentation? How often are level 10
nodes mobilized and removed en bloc with the specimen, and
thus not specifically mentioned in the operative report or
pathology report? How often are nodes in stations 5 and 6
or 2R and 4R removed as one packet but labeled only as
station 5 or 4R and therefore not meeting the predefined
criteria for a complete MLND or SS? The authors per-
formed a secondary analysis to account for this but found
that this only minimally improved the results, demonstrat-
ing that this was not a major factor.
Are we simply operating at such a low level that no
marker of high quality can emerge? In this series, the approx-
imately 185 resections per year were divided among 8 hos-
pitals and 21 surgeons. Only two surgeons had a general
thoracic practice (who in fact performed only a few of the
resections), and all others had a combined cardiac and tho-
racic practice.6 Nevertheless, the situation represents the
reality in the United States, and we have to find metrics and
interventions that work in this environment to improve care.
Reading between the lines, it seems that the major
source of discordance is that we are speaking different lan-
guages, like in the story of the tower of Babel. If our ability
to understand what we mean is limited, then we are clearly
not in position to collectively build a foundation for quality
metrics, at least not with these building blocks. We can’t
implement a quality indicator which might be met in name
but will vary in terms of what is actually done and therefore
not be useful. This is particularly important because most
quality indicators are process measures that are thought to
correlate with actual outcomes but in fact never get reevalu-
ated once introduced to see if they actually do.
Given these difficulties, perhaps we should focus less
on process measures (although this is favored in the United
States) and consider structural measures (as done in Europe).
However, only limited indirect data are available to validate
measures that have been embraced in parts of Europe (e.g.,
presenting each case before a regional multidisciplinary panel
of experts or completing the evaluation within a designated
time frame). Furthermore, there are differences between
health care in Europe and the United States. In much of
Europe, for example, thoracic surgical care is often delivered
in dedicated centers (often former tuberculosis hospitals) that
have some depth to the thoracic team devoted to caring for
these patients. Data from countries like the Netherlands,
where care was dispersed but more recently has became more
regionalized, supports the concept of organized programs.7
It is good that groups like Osarogiagbon et al.5 are
carrying out their work. It is clear that we have a long way to
go and we have not defined simple quality indicators. It is
also clear that we have a major educational challenge to even
get to the point where we can discuss terms and be comfort-
able that we are referring to the same thing. The volume of
literature and the multiple clinical guidelines have not yet
brought about sufficient consistency in care. Perhaps we are
struggling to find ways to improve the quality of care not
despite—but rather because of—the explosion of literature
and the difficulty in staying abreast of it without a dedicated
team of sufficient critical mass.
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